Rhenman & Partners Asset Management’s Health Catalyst HCAT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-300,000	Closed	-$2.78M	–	87
2023 Q4	$2.78M	Sell	300,000 -20,000	-6%	-$163K	0.28%	68
2023 Q3	$3.24M	Hold	320,000	–	–	0.35%	63
2023 Q2	$4M	Sell	320,000 -20,000	-6%	-$238K	0.42%	60
2023 Q1	$3.87M	Buy	340,000 +160,000	+89%	+$2.04M	0.42%	63
2022 Q4	$1.91M	Hold	180,000	–	–	0.2%	83
2022 Q3	$1.59M	Hold	180,000	–	–	0.17%	86
2022 Q2	$2.61M	Hold	180,000	–	–	0.3%	72
2022 Q1	$4.7M	Sell	180,000 -60,000	-25%	-$1.7M	0.46%	63
2021 Q4	$9.73M	Hold	240,000	–	–	0.65%	54
2021 Q3	$12M	Hold	240,000	–	–	0.84%	46
2021 Q2	$13.3M	Buy	240,000 +125,000	+109%	+$6.66M	0.9%	47
2021 Q1	$5.38M	Buy	+115,000	New	+$5.57M	0.38%	72

Other funds holding HCAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rhenman & Partners Asset Management's HCAT Position: Q1 2024 in Review

Rhenman & Partners Asset Management sold out of Health Catalyst (HCAT) in Q1 2024, closing a stake of 300,000 shares — an estimated $2.78M sold.

Rhenman & Partners Asset Management first reported a position in HCAT in Q1 2021 and held it in 12 quarters. The position peaked at $13.3M in Q2 2021. 174 funds tracked by Wall St. Rank hold HCAT as of Q1 2024.

Rhenman & Partners Asset Management reported no remaining Health Catalyst position as of Q1 2024 after selling out during the quarter.
Rhenman & Partners Asset Management sold 300,000 Health Catalyst shares in Q1 2024, an estimated $2.78M.
Rhenman & Partners Asset Management first reported a position in Health Catalyst in Q1 2021 and held it in 12 quarters.
Rhenman & Partners Asset Management's Health Catalyst position peaked at $13.3M in Q2 2021.
174 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2024.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2024, filed 14 May 2024.